Pharmaceutical Companies– tag –
-
Oncology Drug Approval News Flash: FDA grants regular approval to rucaparib for BRCAm mCRPC and approves subcutaneous amivantamab and hyaluronidase-lpuj
FDA approval summary On December 17, 2025, the U.S. Food and Drug Administration (FDA) granted regular approval to rucaparib (Rubraca, pharmaand GmbH) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) associ... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 6 Cancer Screening, Early Detection, and Aging: What to Test, When, and How Far?
Introduction: Screening Is Not Just “The Earlier, the Better” In Parts 1–5, we explored the relationship between aging and cancer from multiple angles: molecular and genetic mechanisms, immune aging, organ-specif In Parts 1–5, we explore... -
Oncology Drug Approval News Flash: Fam-trastuzumab deruxtecan-nxki plus pertuzumab approved as first-line therapy for unresectable or metastatic HER2-positive breast cancer
FDA approval summary On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with un... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 5 Lifestyle and Environmental Factors in Aging and Cancer: What Can We Change, and What Is Hard to Change?
Introduction: Deconstructing Risk Factors In Parts 1–4 of this series, we explored aging and cancer from several angles: In Parts 1–4 of this series, we explored aging and cancer from several angles: What you will learn Introduction: Dec... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 4 Aging and Cancer at the Organ and Tissue Level: Organ Specificity, Sex Differences, Reproductive Aging, and Inter-Organ Crosstalk
Introduction: Why Do Different Organs Develop Different Cancers with Age? In Parts 1–3, we looked at aging and cancer from the perspectives of time, molecular mechanisms, immunity, and the tumor microenvironment. In Parts 1–3, we looked ... -
Oncology Drug Approval News Flash: Niraparib plus abiraterone acetate and prednisone approved for BRCA2-mutated metastatic castration-sensitive prostate cancer
FDA approval summary On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adult patients with deleterious or suspected deleteriou... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 3Immune Aging and the Tumor Microenvironment: How Our Defense System Changes with Age
Introduction: The Triangle of Aging, Cancer, and Immunity In Part 1, we explored why cancer is often described as a “disease of aging” and reviewed the historical and conceptual overlap between the hallmarks of aging and the hallmarks of... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 2 How Aging and Cancer Are Linked at the Molecular and Genetic Levels
Introduction: Zooming in on the “Inner Structure” of Aging Aging and cancer share the same cellular clock—and the same failure modes. Mapping the molecular bridge between senescence and tumor biology reveals the design blueprint for a ne... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 1 Why Is Cancer Called a “Disease of Aging”?
Introduction: Why Revisit “Aging and Cancer” Now? The phrase “cancer is a disease of aging” is something most clinicians and life science professionals have heard countless times. The phrase “cancer is a disease of aging” is something mo... -
Recent ADC Landscape Update Series, Part 3: Merck–Daiichi’s CDH6 ADC R-DXd and DLL3 ADC SHR-4849 – The Next Wave in Ovarian Cancer and SCLC
In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludot In Part 3 of this series, we focus on two “second-wave” ADC programs that have at... -
Recent ADC Landscape Update Series, Part 2: Enhertu in Early HER2-Positive Breast Cancer – What DESTINY-Breast05 and 11 Mean for Future Standards of Care
In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already tr In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-b... -
Recent ADC Landscape Update Series, Part 1: AstraZeneca’s Post-Enhertu Strategy – In-house ADCs, Radiopharma and Cell Therapy to Redefine Oncology
Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. Around 2025, oncology is entering a new phase in which antibody–... -
Oncology Drug Approval News Flash：FDA approves lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma
On December 4, 2025, the U.S. Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol Myers Squibb company), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or ref... -
Big Pharma Mega Deals in the Last Few Months Series Part 6 | A Startup-Side Playbook: Building a Company That Can Partner or Stay Independent
In the previous installments of this series, we looked at recent big pharma transactions through the lenses of oncology, obesity/metabolic disease, re In the previous installments of this series, we looked at recent big pharma transactio... -
Oncology Drug Approval News Flash：FDA grants traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory CLL/SLL after covalent BTK inhibitor therapy
On December 3, 2025, the U.S. Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic l... -
Big Pharma Mega Deals in the Last Few Months Series Part 5 | How Investors Can Read and Use Big Pharma Transactions
When investors follow big pharma transactions, it is tempting to focus on headline numbers: total deal value, takeover premium, “multi-billion” labels. When investors follow big pharma transactions, it is tempting to focus on headline nu... -
Big Pharma Mega Deals in the Last Few Months Series Part 4 | Respiratory and Infectious Disease: From COPD and Rare Lung Disorders to Seasonal Viral Threats
Alongside oncology and metabolic disease, one of the most striking clusters in recent big pharma transactions over the last few months is respiratory and infectious disease. Alongside oncology and metabolic disease, one of the most strik... -
Big Pharma Mega Deals in the Last Few Months Series Part 2 | Next-Generation Oncology: in vivo CAR-T, ADCs, Bispecifics and Oral Biologics
Among the many big pharma transactions announced in the last few months, oncology stands out as the area where activity is both dense and conceptually rich. Among the many big pharma transactions announced in the last few months, oncolog... -
Big Pharma Mega Deals in the Last Few Months Series: Landscape and Thematic Map (Part 1)
Over the last few months, the pharmaceutical and biotech industry has seen a flurry of mega deals, many of them comfortably exceeding the $1 billion m Over the last few months, the pharmaceutical and biotech industry has seen a flurry of... -
Cancer Treatment Introductory–to–Basic Series – Overview
How to Read This 8-Part Series: Seeing the Bigger Picture of Cancer Care The “Cancer Treatment Introductory–to–Basic Series” consists of eight main articles that walk through the big picture of cancer care: overall structur The “Cancer T...
